{"ticker": {"uuid": "78b7c9e9-394e-4bf2-a005-03f743a74d9e", "symbol": "ACTU", "name": "Actuate Therapeutics, Inc. Common stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Johnson & Johnson stock trades steadily as diversified healthcare earnings and pipeline support long", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPMVNqZWZ4M1hzSFBtUUFvbEhNcVk0QXNDQmFwTFFsTmxuTHVFOUxvZ2lSaXV1Mng5ZWJWU0w1QmtFa2UtcnBMUDFjN3lxMllFdG1MNG82Z0xldFd6UHFUc1lWR0F1SnVMQ0luZVhPN1RhZEp6eS1oR3hFZDRPVmxSMkh4VGYySFBiX1o4dlhSQzNmTkdkN1dLLVFXb1EyR0M3OU94TDRaTm9GRG91eWM2OTZIRUhnaWVlZS1TNXhYYjFrZmx4?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-07-18T05:33:28+00:00", "published_display": "18 Jul 2026 05:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard", "summary": "Actuate Therapeutics (ACTU) received a Nasdaq notice on July 15, 2026, indicating its Market Value of Listed Securities fell below the required $50 million minimum for the Nasdaq Global Market. The company has 180 days, until January 11, 2027, to regain compliance by maintaining ", "url": "https://www.tradingview.com/news/tradingview:6f381adaf9df7:0-actuate-therapeutics-disclosed-failure-to-satisfy-a-continued-listing-rule-or-standard/", "source_name": "TradingView", "published_at": "2026-07-17T20:10:43", "published_display": "17 Jul 2026 20:10", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQ3B5MlVsTlBhcXdmUVllazV2SWFHTmRudHVNdFY3RUYtR1FTXzNIV1VYODF0bTMyVThkOE1LZC11TGN2dUxBZzRPTDQxUDVDdF9PWW5VUk1rZVJkdXRjbTQ2MU1wa3BtejZ5NUhWY1dQLUZLS3duak1fMzIxcnNwUmc4X3N5Q1JXMFNQY1J0ZVd5aHF4NHVUQkpnNlNUU1VWcVljNjhGbkFicUNyOXktR0lZWkVxT09oU0VQZnZObG5RMkJDWHh4czRrUktNZFNrZVhKWnF1YTZ2ZmVzTG14WG1n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:17+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Actuate Therapeutics, Inc. \u2013 NASDAQ:ACTU", "summary": "This article provides details on the number of shareholders for Actuate Therapeutics, Inc. (NASDAQ: ACTU). It appears to be a stub or a data point from a financial platform, showing the company's stock market information on Nasdaq. The content primarily consists of navigation and", "url": "https://www.tradingview.com/symbols/NASDAQ-ACTU/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-07-01T23:39:50", "published_display": "01 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 3000E Index", "summary": "Actuate Therapeutics, Inc. (NasdaqGM: ACTU) has been removed from the Russell 3000E Index. This news follows several other announcements on June 29th and 28th detailing its removal from various Russell indices, including the Russell 2000, Russell 2500, and Russell Small Cap Compl", "url": "https://www.marketscreener.com/news/actuate-therapeutics-inc-nasdaqgm-actu-dropped-from-russell-3000e-index-ce7f5fdfda88f323", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T18:09:47", "published_display": "29 Jun 2026 18:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 2500 Index", "summary": "Actuate Therapeutics, Inc. (NasdaqGM: ACTU) has been removed from the Russell 2500 Index, as well as the Russell 3000E Index, Russell Small Cap Completeness Index, Russell 3000 Index, Russell 2000 Index, Russell Small Cap Comp Growth Benchmark, and Russell 3000 Growth Benchmark. ", "url": "https://www.marketscreener.com/news/actuate-therapeutics-inc-nasdaqgm-actu-dropped-from-russell-2500-index-ce7f5fdfda89f626", "source_name": "marketscreener.com", "published_at": "2026-06-29T17:40:58", "published_display": "29 Jun 2026 17:40", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 3000 Index", "summary": "Actuate Therapeutics, Inc. (NasdaqGM: ACTU) has been removed from the Russell 3000 Index, along with several other Russell indices on June 29, 2026. This news comes as the clinical-stage biopharmaceutical company continues to develop therapies for cancer, particularly with its le", "url": "https://www.marketscreener.com/news/actuate-therapeutics-inc-nasdaqgm-actu-dropped-from-russell-3000-index-ce7f5fdfd98cf623", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T10:12:00", "published_display": "29 Jun 2026 10:12", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 2000 Index", "summary": "Actuate Therapeutics, Inc. (NasdaqGM: ACTU) has been removed from the Russell 2000 Index. This follows a series of similar removals from other Russell indices, including the Russell 3000E, Small Cap Completeness, 2500, and 3000 indices. The company, a clinical-stage biopharmaceut", "url": "https://www.marketscreener.com/news/actuate-therapeutics-inc-nasdaqgm-actu-dropped-from-russell-2000-index-ce7f5fdfd98df622", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T10:02:00", "published_display": "29 Jun 2026 10:02", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell 3000 Growth Benchmark", "summary": "Actuate Therapeutics, Inc. (NasdaqGM:ACTU) has been removed from the Russell 3000 Growth Benchmark. This news, published on June 28, 2026, comes as the company continues to develop Elraglusib for various cancer treatments. The stock closed at $1.680, reflecting significant year-t", "url": "https://www.marketscreener.com/news/actuate-therapeutics-inc-nasdaqgm-actu-dropped-from-russell-3000-growth-benchmark-ce7f5fdedb88f622", "source_name": "www.marketscreener.com", "published_at": "2026-06-28T21:31:00", "published_display": "28 Jun 2026 21:31", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Actuate Therapeutics, Inc. \u2013 NASDAQ:ACTU", "summary": "This article focuses on the \"Price to sales forward\" metric for Actuate Therapeutics, Inc. (NASDAQ: ACTU). It appears to be a stub or a data point from a financial platform, showing that this specific financial data point was generated by human input over a particular period. The", "url": "https://www.tradingview.com/symbols/NASDAQ-ACTU/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T07:10:26", "published_display": "27 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Actuate Therapeutics, Inc. \u2013 NASDAQ:ACTU", "summary": "This article focuses on the \"Price to earnings forward\" metric for Actuate Therapeutics, Inc. (NASDAQ: ACTU). The content is primarily a placeholder or incomplete financial data page from TradingView, indicating that specific financial figures for this metric are not presented wi", "url": "https://www.tradingview.com/symbols/NASDAQ-ACTU/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T03:11:14", "published_display": "27 Jun 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACTU Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Actuate Therapeutics, Inc. (ACTU) stock for 2027, based on analyst opinions. It includes current stock performance, historical highs and lows, market capitalization, and upcoming earnings reports, while also addressing frequen", "url": "https://www.tradingview.com/symbols/NASDAQ-ACTU/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T20:10:06", "published_display": "25 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics (ACTU) Finds Its Footing Near Key Support After a Modest Gain - Volatility Smile", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNaXNyVTYxNU82N2tDam9naWE3WFhfOGZWcDVBU1Z2VFZVeW16RmtGWkxxam5hbjBsbXRxVnF5MmFoOG45ZTh0dm9OUzJ1WWV3WVJyZ0w5aGFtQ3lRVS1tM0V4QjFjZW9nejIzTXNRYlk1ZC04cnBRVkVpcXZwRE1mQnpxOGhsMENibmljdWZrcnMyTGRWc3MxenVhR1RqMlN4ODFxQXVHSzRvejV4djRPcTRaUlVJaHctSjliR1l3TXVWeTNVemw4a3BkUHNDdw?oc=5", "source_name": "B\u00f6l\u00fcm Sonu Canavar\u0131", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics Inc (ACTU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Actuate Therapeutics Inc (ACTU). It notes that relevant financial data regarding business segments, regional revenue, and profit contribution has not yet been disclosed by the company. The page also presents current st", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-actu/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T19:10:02", "published_display": "18 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics Inc (ACTU) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Actuate Therapeutics Inc (ACTU), detailing analyst ratings, target prices, and EPS expectations. Four analysts currently rate ACTU as a \"Buy\" with a significant upside potential of +762.07% to a target price of $17.500. The company's", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-actu/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T05:40:26", "published_display": "18 Jun 2026 05:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics Inc (ACTU) Institutional Confidence", "summary": "This article from TradingKey provides details on the institutional confidence in Actuate Therapeutics Inc (ACTU). It lists major institutional shareholders including Bios Equity Partners, Kairos Ventures, and Voss Capital, along with their shareholdings and recent changes. The st", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-actu/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T04:40:26", "published_display": "18 Jun 2026 04:40", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics Inc (ACTU) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Actuate Therapeutics Inc (ACTU), detailing various financial and investment risk metrics. It includes data on volatility, maximum drawdown, Sharpe Ratio, and turnover rates over different periods. The report highlights historical perfor", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-actu/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-18T04:40:26", "published_display": "18 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics, Inc. Financial Disclosures & SEC Filings", "summary": "This article provides a compilation of Actuate Therapeutics, Inc.'s financial disclosures and SEC filings, including Forms 10-K, 10-Q, and press releases. It details the company's financial performance, operational updates, and the critical need for funding to continue operations", "url": "https://www.tradingview.com/symbols/NASDAQ-ACTU/documents/", "source_name": "TradingView", "published_at": "2026-06-13T20:08:41", "published_display": "13 Jun 2026 20:08", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Experimental cancer drug elraglusib joins landmark pediatric neuroblastoma trial", "summary": "Actuate Therapeutics announced that its experimental drug elraglusib has been selected for the European BEACON2 Phase 1/2 clinical trial for high-risk pediatric neuroblastoma. Elraglusib, a GSK-3\u03b2 inhibitor, will be tested in combination with dinutuximab beta and chemotherapy. Th", "url": "https://www.stocktitan.net/news/ACTU/actuate-therapeutics-elraglusib-selected-for-evaluation-in-beacon2-obhg34neq7f5.html", "source_name": "Stock Titan", "published_at": "2026-06-10T14:12:09", "published_display": "10 Jun 2026 14:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Actuate Therapeutics stock rating on trial inclusion By Investing.com", "summary": "H.C. Wainwright reiterated a Buy rating and $15.00 price target on Actuate Therapeutics (NASDAQ:ACTU) after the company announced the inclusion of its elraglusib drug candidate in the BEACON2 trial for pediatric neuroblastoma. This trial, sponsored by Cancer Research UK,", "url": "https://ca.investing.com/news/stock-market-news/hc-wainwright-reiterates-actuate-therapeutics-stock-rating-on-trial-inclusion-93CH-4684103", "source_name": "Investing.com Canada", "published_at": "2026-06-10T11:39:48", "published_display": "10 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics Says Elraglusib to be Evaluated in Phase 1/2 Trial to Find Treatments for Pediatric Neuroblastoma", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/actuate-therapeutics-says-elraglusib-evaluated-122551966.html", "source_name": "MT Newswires", "published_at": "2026-06-09T12:25:51+00:00", "published_display": "09 Jun 2026 12:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics\u2019 Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma", "summary": "Actuate Therapeutics announced that its drug, elraglusib, will be evaluated in the BEACON2 clinical trial for high-risk pediatric neuroblastoma. This multi-arm, multi-stage Phase 1/2 platform trial will assess elraglusib in combination with dinutuximab beta and chemotherapy. The ", "url": "https://www.globenewswire.com/news-release/2026/06/09/3308735/0/en/actuate-therapeutics-elraglusib-selected-for-evaluation-in-beacon2-trial-for-high-risk-pediatric-neuroblastoma.html", "source_name": "GlobeNewswire", "published_at": "2026-06-09T12:09:55", "published_display": "09 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics to Evaluate Elraglusib in BEACON2 Clinical Trial for Relapsed Neuroblastoma in Partnership with Cancer Research UK Clinical Trials Unit", "summary": "Actuate Therapeutics announced that its investigational drug elraglusib will be evaluated in the BEACON2 trial, a Phase 1/2 clinical study sponsored by Cancer Research UK for relapsed and refractory neuroblastoma in pediatric patients. The trial aims to assess elraglusib in combi", "url": "https://www.quiverquant.com/news/Actuate+Therapeutics+to+Evaluate+Elraglusib+in+BEACON2+Clinical+Trial+for+Relapsed+Neuroblastoma+in+Partnership+with+Cancer+Research+UK+Clinical+Trials+Unit", "source_name": "Quiver Quantitative", "published_at": "2026-06-09T11:52:00", "published_display": "09 Jun 2026 11:52", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer", "summary": "Actuate Therapeutics announced compelling clinical and biomarker data for its investigational drug elraglusib from ASCO poster presentations. The data highlights significant improvements in overall survival for metastatic pancreatic cancer patients with specific gene mutations wh", "url": "https://finance.yahoo.com/sectors/healthcare/articles/actuate-therapeutics-announces-asco-poster-110000956.html", "source_name": "Market source", "published_at": "2026-06-03T23:39:48", "published_display": "03 Jun 2026 23:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics Announces ASCO Poster Presentations", "summary": "Actuate Therapeutics announced two poster presentations at the 2026 ASCO Annual Meeting, detailing compelling clinical and biomarker data for its drug, elraglusib, in treating metastatic pancreatic cancer. The data demonstrated significant improvements in overall survival for pat", "url": "https://www.globenewswire.com/news-release/2026/06/01/3304175/0/en/actuate-therapeutics-announces-asco-poster-presentations-demonstrating-compelling-clinical-and-biomarker-data-for-elraglusib-in-first-line-metastatic-pancreatic-cancer.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T10:40:12", "published_display": "01 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Study: new drug nearly doubles 1-year survival in pancreatic cancer", "summary": "Actuate Therapeutics announced promising Phase 2 clinical and biomarker data for its drug elraglusib in first-line metastatic pancreatic cancer at ASCO 2026. The data showed that elraglusib, when combined with chemotherapy regimens like gemcitabine/nab-paclitaxel (GnP) or FOLFIRI", "url": "https://www.stocktitan.net/news/ACTU/actuate-therapeutics-announces-asco-poster-presentations-b6v5yme067rw.html", "source_name": "Stock Titan", "published_at": "2026-06-01T04:10:20", "published_display": "01 Jun 2026 04:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics elects directors and ratifies auditor at annual meeting By Investing.com", "summary": "Actuate Therapeutics, Inc. held its annual meeting, electing Aaron G.L. Fletcher, Ph.D., and Jason Keyes as Class II directors for three-year terms and ratifying Crowe LLP as its independent auditor. The company, trading at $2.38 with a market cap of $57.9 million, has declined 7", "url": "https://m.in.investing.com/news/sec-filings/actuate-therapeutics-elects-directors-and-ratifies-auditor-at-annual-meeting-93CH-5423824?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-05-23T21:40:11", "published_display": "23 May 2026 21:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics, Inc. Files Form 8-K Current Report with SEC Detailing Company Information and Nasdaq Listing", "summary": "Actuate Therapeutics, Inc. (NASDAQ: ACTU) filed a Form 8-K with the SEC on May 21, 2026, detailing the results of a shareholder vote, which showed strong support for the election of directors. The filing confirms the company's status as a Delaware corporation, its listing on NASD", "url": "https://www.minichart.com.sg/2026/05/23/actuate-therapeutics-inc-files-form-8-k-current-report-with-sec-detailing-company-information-and-nasdaq-listing/", "source_name": "Minichart", "published_at": "2026-05-23T10:39:21", "published_display": "23 May 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics elects directors and ratifies auditor at annual meeting", "summary": "Actuate Therapeutics (NASDAQ:ACTU) held its annual meeting where shareholders elected Aaron G.L. Fletcher, Ph.D., and Jason Keyes as Class II directors, and ratified Crowe LLP as the independent auditor for the fiscal year ending December 31, 2026. Despite a significant share pri", "url": "https://m.investing.com/news/sec-filings/actuate-therapeutics-elects-directors-and-ratifies-auditor-at-annual-meeting-93CH-4707635?ampMode=1", "source_name": "Investing.com", "published_at": "2026-05-22T21:10:29", "published_display": "22 May 2026 21:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Actuate Therapeutics, Inc. (ACTU)", "summary": "LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Pyxis Oncology (PYXS) with a $6.00 price target, highlighting a strong buy consensus among analysts. H.C. Wainwright analyst Swayampakula Ramakanth also maintained a Buy rating on Actuate Therapeutics, Inc. (ACTU) wit", "url": "https://www.theglobeandmail.com/investing/markets/stocks/PYXS/pressreleases/2010141/analysts-offer-insights-on-healthcare-companies-pyxis-oncology-pyxs-and-actuate-therapeutics-inc-actu/", "source_name": "The Globe and Mail", "published_at": "2026-05-21T09:09:17", "published_display": "21 May 2026 09:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co.", "summary": "HC Wainwright & Co. has reiterated its Buy rating for Actuate Therapeutics, maintaining a price target of $15.00 per share. This indicates continued confidence in the company's financial prospects and potential stock performance according to the analyst firm.", "url": "https://www.moomoo.com/news/post/70195699/actuate-therapeutics-price-target-maintained-with-a-15-00-share?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-05-18T18:39:46", "published_display": "18 May 2026 18:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Revolution\u2019s 'miracle' pancreatic cancer drug be topped? Immuneering, Actuate say yes", "summary": "Revolution Medicines' RAS inhibitor recently doubled survival in a Phase 3 pancreatic cancer trial, a significant breakthrough for a deadly disease. However, companies like Immuneering, Actuate Therapeutics, and Erasca are developing alternative approaches focusing on improved to", "url": "https://www.biospace.com/drug-development/can-revolutions-miracle-pancreatic-cancer-drug-be-topped-immuneering-actuate-say-yes", "source_name": "BioSpace", "published_at": "2026-05-18T14:11:18", "published_display": "18 May 2026 14:11", "sentiment": "positive", "sentiment_pct": 86, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/actuate-therapeutics-announces-fda-clearance-110000795.html", "source_name": "GlobeNewswire", "published_at": "2026-05-11T11:00:00+00:00", "published_display": "11 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/actuate-therapeutics-announces-key-appointment-124500703.html", "source_name": "GlobeNewswire", "published_at": "2026-05-06T12:45:00+00:00", "published_display": "06 May 2026 12:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "NEWSLETTER: Actuate Therapeutics drug improves survival odds in pancreatic cancer trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxPeWRMRGo0QS1MT2paMm55bG5tLTh4cVhoOVE1dS1QZ0o1bEJWdXpwUDFiVGVHb3BmaHhmOWR3RC1udF9uNGhvZGk1R2tzREtudVpqMkhldFI4bWhjZk5ZeWhCc3d2N2hFekh1MXBCOUFoSDJOenRUSVZ3eVlTVEpMZnp5LWNLWFdXLVc0amRWdVg5QnN1Wnp6MXEwTXcxWmFuT1lzS0c2b1R5enBUdWJ0TjVUWU5IZUM2V2UzTTdFZS1VN0xyLXpOTXhNemdnUDF2TFg5cElJU1hvWWZI?oc=5", "source_name": "Reuters", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "$ACTU stock is up 31% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxON3hCMm5fNkRlbUxvTzJTOEl0dWF1a19KNmhWMjhMWk0yWkpRcm04Q0J1cWZMdXFyV3V0WVQ0bnRKTUNDTXJTRHBTOWVucFR0MVE3ZXh3OUxuQ0lfOEtXTFBFbjZSU3RRZDJrSjN5OFV6cWpMTUxpbVNjaExuUEZUcXVKS05MTHdVTFA2cFpqaGhUdFlGT1ZMbUZoWDA2QzJB?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "B.Riley cuts Actuate Therapeutics stock price target on revenue timing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQTkF4dWdyNzRvVm4xVXFqZnNfaHhsd0RzVE5tU0xKdjFNNmJSTWxWd0lzZm9MalBRcFB3QUNtckY5cVVoeENySHQxbll2NUVYZmtHZnVGN3VXaHg4SDFTajVsTWZyVHY3eXZqd2N4VTUxS2RzUWc2bmZoeU5YSGtYVnVXbTFoekdlRzI2VTBPNHhORVFKWUlmdkIwSk13d3ZqaGlEbWpKdW8zRkRqSENadGk0X3hqcEZHdjdkbUZTcnBGMnZrSzd6cg?oc=5", "source_name": "Investing.com", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics, Inc. Announces Presentation at Citizens Life Sciences Conference in Miami Beach", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOWWx5YkJxZDhycWlVcFUxTHdMQzR4MGtibFFtVGJuUmk5T3JrNTNFTTFsckFzOF9iQ2dNTGJsYU5EYzI5LVRSS19kc053eFV1ajV2WkVQZW5BdUZPdWItOENVOFcxc2tuQmY2dlFXeElCX3dOalRUMjNodHlDemxKY1Rkb2FMOHRFek52RWV4YXdnUXlWakZ0NU1nXzBvbzlGTmw4N2RoaUhZSHdUZUhlZjFPMlNSRGlQNWhwVHB3MHdjTEM2RFJXbWNxRGJlb01MR2c?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molina Healthcare Stock Craters. Why Its Earnings Outlook Is So Bleak.", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPX1JJd3MzSGZ4Tl9ZWUduMTAtSUNrdVJDZFE2YnVGZzhvTUt6OXZNcHFPSG1LaWJ5a3NnQV9VeEZtYlNMVVlvaXZOanJreFVOcTd0U0phaUdhQUxjbFFwazc5S0ZYY1hWN25WalhXUGVQZEh5UnB3UDVWSzRoS3VsWnk5ek11X0k?oc=5", "source_name": "Barron's", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Actuate Therapeutics' (NASDAQ:ACTU) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxNWDVqQ1lYblVRNmN2cUFXVmlnLU85TjhiUDRxOTVLZDA4eEhob2pjWGUtb2xYZ3R3VU0xLXhOUXJMcVBiVXdGRldOR1M0Vkgwckd0dEhxeTY1cVFkLXdLSkZLNWNaRHp3aHVTdTVxX2ZhbVhPYXlBS1BNNXljd2p2dXJ2UQ?oc=5", "source_name": "Market source", "published_at": "2025-11-15T08:00:00+00:00", "published_display": "15 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Applied Materials Stock Rallies Following An Upgrade From Morgan Stanley: Here\u2019s The New Price Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOMHhuc0RxRjNNQkd5aHR0S3diS1BYZG5ndGlVbnZfOWJLM1hZVUVTbE0xamlOX2RaXzU5LWFvdDJxMTdMcVprMERlWEhMV1FSX2FPdGtscTNBMVZmZ2gzcmpfZWdWcFFjRWV2Wnl1REdRVWdDcU5zd0Q5Q0VDcGp3WTRHSjExSzZOekxyaUMxaHJkNmhlVWh5NTBzQ2gybTdCVEhpUEF6RV84NW02TjBFejhiQkFBVjVvYVdnbGVTcG5reHlfbUVybVB5aGxwNFI5WHc?oc=5", "source_name": "Stocktwits", "published_at": "2025-09-22T17:19:49+00:00", "published_display": "22 Sep 2025 17:19", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics Reports Positive Progress on Elraglusib as Backbone Therapy for Pancreatic Cancer Amid Ongoing Clinical Trials and Financing Milestone", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwJBVV95cUxOSU45c1F6Rmw5LWlqeUZyMUYyTnpYT1N0NjJjUkFiTElkRjFscThBeHg2bk1TNmowNTZLNk9tTXFoTVhURzl3NWVZeUgtb1ZjelZrbXFMQnY2OVE1U3JvQTNzekxhLXpuVmd5TVJhdXdFUER3UktSb21kWTgxQ0VneWlrZm1xQjZ0elZUNEY3ZXhyQnZlY0FNeGhEeUJTdDMwVlRpOU1WR3BjcTFEZDNJcVRUNlo4VEdkZmZ6Z3F1dEMtMGVmY2NOVjYwVXdCdEtGbTh0TEdoYkRIOWg5X0pCdXZ5Y0JjalM2Z3ZDYlZCUDF6TFF5QXlhR2xvMkNrVHZ0T0V4eUsweklJYWhsWkdJSnJiMnhqdkk?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-09-22T07:00:00+00:00", "published_display": "22 Sep 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Richtech Robotics Stock Sees Retail Chatter Double In A Day: Analyst Says Company's Longer-Term Visibility Is Improving", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNVXNwWjlGVm90VXg3MVJYZkNwZnRKNzVDRmVwdFVhbFdvTlBBNmJsTTdIYmZQOUZnc3hZcDNCRkYtSG5FTlAxdFhTQ19FYks5R3hVbFRTNzdtOEo3SXdkWXVfdnZtLWtkZnJpazduWG53MnJlVHVpcjh1RVljcFZHb01iUnRxRUIzMzJqT0g4bU40VnlQNlBmMjlGY283MGFEd1BuRDZyb3QzUEdLQzhfYWFzLUlqX3NheHR0Yw?oc=5", "source_name": "Stocktwits", "published_at": "2025-09-22T07:00:00+00:00", "published_display": "22 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Johnson & Johnson stock trades steadily as diversified healthcare earnings and pipeline support long", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPMVNqZWZ4M1hzSFBtUUFvbEhNcVk0QXNDQmFwTFFsTmxuTHVFOUxvZ2lSaXV1Mng5ZWJWU0w1QmtFa2UtcnBMUDFjN3lxMllFdG1MNG82Z0xldFd6UHFUc1lWR0F1SnVMQ0luZVhPN1RhZEp6eS1oR3hFZDRPVmxSMkh4VGYySFBiX1o4dlhSQzNmTkdkN1dLLVFXb1EyR0M3OU94TDRaTm9GRG91eWM2OTZIRUhnaWVlZS1TNXhYYjFrZmx4?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-07-18T05:33:28+00:00", "published_display": "18 Jul 2026 05:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard", "summary": "Actuate Therapeutics (ACTU) received a Nasdaq notice on July 15, 2026, indicating its Market Value of Listed Securities fell below the required $50 million minimum for the Nasdaq Global Market. The company has 180 days, until January 11, 2027, to regain compliance by maintaining ", "url": "https://www.tradingview.com/news/tradingview:6f381adaf9df7:0-actuate-therapeutics-disclosed-failure-to-satisfy-a-continued-listing-rule-or-standard/", "source_name": "TradingView", "published_at": "2026-07-17T20:10:43", "published_display": "17 Jul 2026 20:10", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQ3B5MlVsTlBhcXdmUVllazV2SWFHTmRudHVNdFY3RUYtR1FTXzNIV1VYODF0bTMyVThkOE1LZC11TGN2dUxBZzRPTDQxUDVDdF9PWW5VUk1rZVJkdXRjbTQ2MU1wa3BtejZ5NUhWY1dQLUZLS3duak1fMzIxcnNwUmc4X3N5Q1JXMFNQY1J0ZVd5aHF4NHVUQkpnNlNUU1VWcVljNjhGbkFicUNyOXktR0lZWkVxT09oU0VQZnZObG5RMkJDWHh4czRrUktNZFNrZVhKWnF1YTZ2ZmVzTG14WG1n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:17+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Actuate Therapeutics, Inc. \u2013 NASDAQ:ACTU", "summary": "This article provides details on the number of shareholders for Actuate Therapeutics, Inc. (NASDAQ: ACTU). It appears to be a stub or a data point from a financial platform, showing the company's stock market information on Nasdaq. The content primarily consists of navigation and", "url": "https://www.tradingview.com/symbols/NASDAQ-ACTU/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-07-01T23:39:50", "published_display": "01 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 3000E Index", "summary": "Actuate Therapeutics, Inc. (NasdaqGM: ACTU) has been removed from the Russell 3000E Index. This news follows several other announcements on June 29th and 28th detailing its removal from various Russell indices, including the Russell 2000, Russell 2500, and Russell Small Cap Compl", "url": "https://www.marketscreener.com/news/actuate-therapeutics-inc-nasdaqgm-actu-dropped-from-russell-3000e-index-ce7f5fdfda88f323", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T18:09:47", "published_display": "29 Jun 2026 18:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 2500 Index", "summary": "Actuate Therapeutics, Inc. (NasdaqGM: ACTU) has been removed from the Russell 2500 Index, as well as the Russell 3000E Index, Russell Small Cap Completeness Index, Russell 3000 Index, Russell 2000 Index, Russell Small Cap Comp Growth Benchmark, and Russell 3000 Growth Benchmark. ", "url": "https://www.marketscreener.com/news/actuate-therapeutics-inc-nasdaqgm-actu-dropped-from-russell-2500-index-ce7f5fdfda89f626", "source_name": "marketscreener.com", "published_at": "2026-06-29T17:40:58", "published_display": "29 Jun 2026 17:40", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 3000 Index", "summary": "Actuate Therapeutics, Inc. (NasdaqGM: ACTU) has been removed from the Russell 3000 Index, along with several other Russell indices on June 29, 2026. This news comes as the clinical-stage biopharmaceutical company continues to develop therapies for cancer, particularly with its le", "url": "https://www.marketscreener.com/news/actuate-therapeutics-inc-nasdaqgm-actu-dropped-from-russell-3000-index-ce7f5fdfd98cf623", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T10:12:00", "published_display": "29 Jun 2026 10:12", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 2000 Index", "summary": "Actuate Therapeutics, Inc. (NasdaqGM: ACTU) has been removed from the Russell 2000 Index. This follows a series of similar removals from other Russell indices, including the Russell 3000E, Small Cap Completeness, 2500, and 3000 indices. The company, a clinical-stage biopharmaceut", "url": "https://www.marketscreener.com/news/actuate-therapeutics-inc-nasdaqgm-actu-dropped-from-russell-2000-index-ce7f5fdfd98df622", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T10:02:00", "published_display": "29 Jun 2026 10:02", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics, Inc.(NasdaqGM:ACTU) dropped from Russell 3000 Growth Benchmark", "summary": "Actuate Therapeutics, Inc. (NasdaqGM:ACTU) has been removed from the Russell 3000 Growth Benchmark. This news, published on June 28, 2026, comes as the company continues to develop Elraglusib for various cancer treatments. The stock closed at $1.680, reflecting significant year-t", "url": "https://www.marketscreener.com/news/actuate-therapeutics-inc-nasdaqgm-actu-dropped-from-russell-3000-growth-benchmark-ce7f5fdedb88f622", "source_name": "www.marketscreener.com", "published_at": "2026-06-28T21:31:00", "published_display": "28 Jun 2026 21:31", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Actuate Therapeutics, Inc. \u2013 NASDAQ:ACTU", "summary": "This article focuses on the \"Price to sales forward\" metric for Actuate Therapeutics, Inc. (NASDAQ: ACTU). It appears to be a stub or a data point from a financial platform, showing that this specific financial data point was generated by human input over a particular period. The", "url": "https://www.tradingview.com/symbols/NASDAQ-ACTU/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T07:10:26", "published_display": "27 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Actuate Therapeutics, Inc. \u2013 NASDAQ:ACTU", "summary": "This article focuses on the \"Price to earnings forward\" metric for Actuate Therapeutics, Inc. (NASDAQ: ACTU). The content is primarily a placeholder or incomplete financial data page from TradingView, indicating that specific financial figures for this metric are not presented wi", "url": "https://www.tradingview.com/symbols/NASDAQ-ACTU/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T03:11:14", "published_display": "27 Jun 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ACTU Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Actuate Therapeutics, Inc. (ACTU) stock for 2027, based on analyst opinions. It includes current stock performance, historical highs and lows, market capitalization, and upcoming earnings reports, while also addressing frequen", "url": "https://www.tradingview.com/symbols/NASDAQ-ACTU/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T20:10:06", "published_display": "25 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics (ACTU) Finds Its Footing Near Key Support After a Modest Gain - Volatility Smile", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNaXNyVTYxNU82N2tDam9naWE3WFhfOGZWcDVBU1Z2VFZVeW16RmtGWkxxam5hbjBsbXRxVnF5MmFoOG45ZTh0dm9OUzJ1WWV3WVJyZ0w5aGFtQ3lRVS1tM0V4QjFjZW9nejIzTXNRYlk1ZC04cnBRVkVpcXZwRE1mQnpxOGhsMENibmljdWZrcnMyTGRWc3MxenVhR1RqMlN4ODFxQXVHSzRvejV4djRPcTRaUlVJaHctSjliR1l3TXVWeTNVemw4a3BkUHNDdw?oc=5", "source_name": "B\u00f6l\u00fcm Sonu Canavar\u0131", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics Inc (ACTU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Actuate Therapeutics Inc (ACTU). It notes that relevant financial data regarding business segments, regional revenue, and profit contribution has not yet been disclosed by the company. The page also presents current st", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-actu/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T19:10:02", "published_display": "18 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics Inc (ACTU) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Actuate Therapeutics Inc (ACTU), detailing analyst ratings, target prices, and EPS expectations. Four analysts currently rate ACTU as a \"Buy\" with a significant upside potential of +762.07% to a target price of $17.500. The company's", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-actu/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T05:40:26", "published_display": "18 Jun 2026 05:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics Inc (ACTU) Institutional Confidence", "summary": "This article from TradingKey provides details on the institutional confidence in Actuate Therapeutics Inc (ACTU). It lists major institutional shareholders including Bios Equity Partners, Kairos Ventures, and Voss Capital, along with their shareholdings and recent changes. The st", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-actu/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T04:40:26", "published_display": "18 Jun 2026 04:40", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics Inc (ACTU) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Actuate Therapeutics Inc (ACTU), detailing various financial and investment risk metrics. It includes data on volatility, maximum drawdown, Sharpe Ratio, and turnover rates over different periods. The report highlights historical perfor", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-actu/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-18T04:40:26", "published_display": "18 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics, Inc. Financial Disclosures & SEC Filings", "summary": "This article provides a compilation of Actuate Therapeutics, Inc.'s financial disclosures and SEC filings, including Forms 10-K, 10-Q, and press releases. It details the company's financial performance, operational updates, and the critical need for funding to continue operations", "url": "https://www.tradingview.com/symbols/NASDAQ-ACTU/documents/", "source_name": "TradingView", "published_at": "2026-06-13T20:08:41", "published_display": "13 Jun 2026 20:08", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Experimental cancer drug elraglusib joins landmark pediatric neuroblastoma trial", "summary": "Actuate Therapeutics announced that its experimental drug elraglusib has been selected for the European BEACON2 Phase 1/2 clinical trial for high-risk pediatric neuroblastoma. Elraglusib, a GSK-3\u03b2 inhibitor, will be tested in combination with dinutuximab beta and chemotherapy. Th", "url": "https://www.stocktitan.net/news/ACTU/actuate-therapeutics-elraglusib-selected-for-evaluation-in-beacon2-obhg34neq7f5.html", "source_name": "Stock Titan", "published_at": "2026-06-10T14:12:09", "published_display": "10 Jun 2026 14:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Actuate Therapeutics stock rating on trial inclusion By Investing.com", "summary": "H.C. Wainwright reiterated a Buy rating and $15.00 price target on Actuate Therapeutics (NASDAQ:ACTU) after the company announced the inclusion of its elraglusib drug candidate in the BEACON2 trial for pediatric neuroblastoma. This trial, sponsored by Cancer Research UK,", "url": "https://ca.investing.com/news/stock-market-news/hc-wainwright-reiterates-actuate-therapeutics-stock-rating-on-trial-inclusion-93CH-4684103", "source_name": "Investing.com Canada", "published_at": "2026-06-10T11:39:48", "published_display": "10 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics Says Elraglusib to be Evaluated in Phase 1/2 Trial to Find Treatments for Pediatric Neuroblastoma", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/actuate-therapeutics-says-elraglusib-evaluated-122551966.html", "source_name": "MT Newswires", "published_at": "2026-06-09T12:25:51+00:00", "published_display": "09 Jun 2026 12:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics\u2019 Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma", "summary": "Actuate Therapeutics announced that its drug, elraglusib, will be evaluated in the BEACON2 clinical trial for high-risk pediatric neuroblastoma. This multi-arm, multi-stage Phase 1/2 platform trial will assess elraglusib in combination with dinutuximab beta and chemotherapy. The ", "url": "https://www.globenewswire.com/news-release/2026/06/09/3308735/0/en/actuate-therapeutics-elraglusib-selected-for-evaluation-in-beacon2-trial-for-high-risk-pediatric-neuroblastoma.html", "source_name": "GlobeNewswire", "published_at": "2026-06-09T12:09:55", "published_display": "09 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics to Evaluate Elraglusib in BEACON2 Clinical Trial for Relapsed Neuroblastoma in Partnership with Cancer Research UK Clinical Trials Unit", "summary": "Actuate Therapeutics announced that its investigational drug elraglusib will be evaluated in the BEACON2 trial, a Phase 1/2 clinical study sponsored by Cancer Research UK for relapsed and refractory neuroblastoma in pediatric patients. The trial aims to assess elraglusib in combi", "url": "https://www.quiverquant.com/news/Actuate+Therapeutics+to+Evaluate+Elraglusib+in+BEACON2+Clinical+Trial+for+Relapsed+Neuroblastoma+in+Partnership+with+Cancer+Research+UK+Clinical+Trials+Unit", "source_name": "Quiver Quantitative", "published_at": "2026-06-09T11:52:00", "published_display": "09 Jun 2026 11:52", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer", "summary": "Actuate Therapeutics announced compelling clinical and biomarker data for its investigational drug elraglusib from ASCO poster presentations. The data highlights significant improvements in overall survival for metastatic pancreatic cancer patients with specific gene mutations wh", "url": "https://finance.yahoo.com/sectors/healthcare/articles/actuate-therapeutics-announces-asco-poster-110000956.html", "source_name": "Market source", "published_at": "2026-06-03T23:39:48", "published_display": "03 Jun 2026 23:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics Announces ASCO Poster Presentations", "summary": "Actuate Therapeutics announced two poster presentations at the 2026 ASCO Annual Meeting, detailing compelling clinical and biomarker data for its drug, elraglusib, in treating metastatic pancreatic cancer. The data demonstrated significant improvements in overall survival for pat", "url": "https://www.globenewswire.com/news-release/2026/06/01/3304175/0/en/actuate-therapeutics-announces-asco-poster-presentations-demonstrating-compelling-clinical-and-biomarker-data-for-elraglusib-in-first-line-metastatic-pancreatic-cancer.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T10:40:12", "published_display": "01 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Study: new drug nearly doubles 1-year survival in pancreatic cancer", "summary": "Actuate Therapeutics announced promising Phase 2 clinical and biomarker data for its drug elraglusib in first-line metastatic pancreatic cancer at ASCO 2026. The data showed that elraglusib, when combined with chemotherapy regimens like gemcitabine/nab-paclitaxel (GnP) or FOLFIRI", "url": "https://www.stocktitan.net/news/ACTU/actuate-therapeutics-announces-asco-poster-presentations-b6v5yme067rw.html", "source_name": "Stock Titan", "published_at": "2026-06-01T04:10:20", "published_display": "01 Jun 2026 04:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics elects directors and ratifies auditor at annual meeting By Investing.com", "summary": "Actuate Therapeutics, Inc. held its annual meeting, electing Aaron G.L. Fletcher, Ph.D., and Jason Keyes as Class II directors for three-year terms and ratifying Crowe LLP as its independent auditor. The company, trading at $2.38 with a market cap of $57.9 million, has declined 7", "url": "https://m.in.investing.com/news/sec-filings/actuate-therapeutics-elects-directors-and-ratifies-auditor-at-annual-meeting-93CH-5423824?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-05-23T21:40:11", "published_display": "23 May 2026 21:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics, Inc. Files Form 8-K Current Report with SEC Detailing Company Information and Nasdaq Listing", "summary": "Actuate Therapeutics, Inc. (NASDAQ: ACTU) filed a Form 8-K with the SEC on May 21, 2026, detailing the results of a shareholder vote, which showed strong support for the election of directors. The filing confirms the company's status as a Delaware corporation, its listing on NASD", "url": "https://www.minichart.com.sg/2026/05/23/actuate-therapeutics-inc-files-form-8-k-current-report-with-sec-detailing-company-information-and-nasdaq-listing/", "source_name": "Minichart", "published_at": "2026-05-23T10:39:21", "published_display": "23 May 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics elects directors and ratifies auditor at annual meeting", "summary": "Actuate Therapeutics (NASDAQ:ACTU) held its annual meeting where shareholders elected Aaron G.L. Fletcher, Ph.D., and Jason Keyes as Class II directors, and ratified Crowe LLP as the independent auditor for the fiscal year ending December 31, 2026. Despite a significant share pri", "url": "https://m.investing.com/news/sec-filings/actuate-therapeutics-elects-directors-and-ratifies-auditor-at-annual-meeting-93CH-4707635?ampMode=1", "source_name": "Investing.com", "published_at": "2026-05-22T21:10:29", "published_display": "22 May 2026 21:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Actuate Therapeutics, Inc. (ACTU)", "summary": "LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Pyxis Oncology (PYXS) with a $6.00 price target, highlighting a strong buy consensus among analysts. H.C. Wainwright analyst Swayampakula Ramakanth also maintained a Buy rating on Actuate Therapeutics, Inc. (ACTU) wit", "url": "https://www.theglobeandmail.com/investing/markets/stocks/PYXS/pressreleases/2010141/analysts-offer-insights-on-healthcare-companies-pyxis-oncology-pyxs-and-actuate-therapeutics-inc-actu/", "source_name": "The Globe and Mail", "published_at": "2026-05-21T09:09:17", "published_display": "21 May 2026 09:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co.", "summary": "HC Wainwright & Co. has reiterated its Buy rating for Actuate Therapeutics, maintaining a price target of $15.00 per share. This indicates continued confidence in the company's financial prospects and potential stock performance according to the analyst firm.", "url": "https://www.moomoo.com/news/post/70195699/actuate-therapeutics-price-target-maintained-with-a-15-00-share?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-05-18T18:39:46", "published_display": "18 May 2026 18:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Revolution\u2019s 'miracle' pancreatic cancer drug be topped? Immuneering, Actuate say yes", "summary": "Revolution Medicines' RAS inhibitor recently doubled survival in a Phase 3 pancreatic cancer trial, a significant breakthrough for a deadly disease. However, companies like Immuneering, Actuate Therapeutics, and Erasca are developing alternative approaches focusing on improved to", "url": "https://www.biospace.com/drug-development/can-revolutions-miracle-pancreatic-cancer-drug-be-topped-immuneering-actuate-say-yes", "source_name": "BioSpace", "published_at": "2026-05-18T14:11:18", "published_display": "18 May 2026 14:11", "sentiment": "positive", "sentiment_pct": 86, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/actuate-therapeutics-announces-fda-clearance-110000795.html", "source_name": "GlobeNewswire", "published_at": "2026-05-11T11:00:00+00:00", "published_display": "11 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/actuate-therapeutics-announces-key-appointment-124500703.html", "source_name": "GlobeNewswire", "published_at": "2026-05-06T12:45:00+00:00", "published_display": "06 May 2026 12:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NEWSLETTER: Actuate Therapeutics drug improves survival odds in pancreatic cancer trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxPeWRMRGo0QS1MT2paMm55bG5tLTh4cVhoOVE1dS1QZ0o1bEJWdXpwUDFiVGVHb3BmaHhmOWR3RC1udF9uNGhvZGk1R2tzREtudVpqMkhldFI4bWhjZk5ZeWhCc3d2N2hFekh1MXBCOUFoSDJOenRUSVZ3eVlTVEpMZnp5LWNLWFdXLVc0amRWdVg5QnN1Wnp6MXEwTXcxWmFuT1lzS0c2b1R5enBUdWJ0TjVUWU5IZUM2V2UzTTdFZS1VN0xyLXpOTXhNemdnUDF2TFg5cElJU1hvWWZI?oc=5", "source_name": "Reuters", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$ACTU stock is up 31% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxON3hCMm5fNkRlbUxvTzJTOEl0dWF1a19KNmhWMjhMWk0yWkpRcm04Q0J1cWZMdXFyV3V0WVQ0bnRKTUNDTXJTRHBTOWVucFR0MVE3ZXh3OUxuQ0lfOEtXTFBFbjZSU3RRZDJrSjN5OFV6cWpMTUxpbVNjaExuUEZUcXVKS05MTHdVTFA2cFpqaGhUdFlGT1ZMbUZoWDA2QzJB?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "B.Riley cuts Actuate Therapeutics stock price target on revenue timing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQTkF4dWdyNzRvVm4xVXFqZnNfaHhsd0RzVE5tU0xKdjFNNmJSTWxWd0lzZm9MalBRcFB3QUNtckY5cVVoeENySHQxbll2NUVYZmtHZnVGN3VXaHg4SDFTajVsTWZyVHY3eXZqd2N4VTUxS2RzUWc2bmZoeU5YSGtYVnVXbTFoekdlRzI2VTBPNHhORVFKWUlmdkIwSk13d3ZqaGlEbWpKdW8zRkRqSENadGk0X3hqcEZHdjdkbUZTcnBGMnZrSzd6cg?oc=5", "source_name": "Investing.com", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics, Inc. Announces Presentation at Citizens Life Sciences Conference in Miami Beach", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOWWx5YkJxZDhycWlVcFUxTHdMQzR4MGtibFFtVGJuUmk5T3JrNTNFTTFsckFzOF9iQ2dNTGJsYU5EYzI5LVRSS19kc053eFV1ajV2WkVQZW5BdUZPdWItOENVOFcxc2tuQmY2dlFXeElCX3dOalRUMjNodHlDemxKY1Rkb2FMOHRFek52RWV4YXdnUXlWakZ0NU1nXzBvbzlGTmw4N2RoaUhZSHdUZUhlZjFPMlNSRGlQNWhwVHB3MHdjTEM2RFJXbWNxRGJlb01MR2c?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molina Healthcare Stock Craters. Why Its Earnings Outlook Is So Bleak.", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPX1JJd3MzSGZ4Tl9ZWUduMTAtSUNrdVJDZFE2YnVGZzhvTUt6OXZNcHFPSG1LaWJ5a3NnQV9VeEZtYlNMVVlvaXZOanJreFVOcTd0U0phaUdhQUxjbFFwazc5S0ZYY1hWN25WalhXUGVQZEh5UnB3UDVWSzRoS3VsWnk5ek11X0k?oc=5", "source_name": "Barron's", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Actuate Therapeutics' (NASDAQ:ACTU) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxNWDVqQ1lYblVRNmN2cUFXVmlnLU85TjhiUDRxOTVLZDA4eEhob2pjWGUtb2xYZ3R3VU0xLXhOUXJMcVBiVXdGRldOR1M0Vkgwckd0dEhxeTY1cVFkLXdLSkZLNWNaRHp3aHVTdTVxX2ZhbVhPYXlBS1BNNXljd2p2dXJ2UQ?oc=5", "source_name": "Market source", "published_at": "2025-11-15T08:00:00+00:00", "published_display": "15 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Applied Materials Stock Rallies Following An Upgrade From Morgan Stanley: Here\u2019s The New Price Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOMHhuc0RxRjNNQkd5aHR0S3diS1BYZG5ndGlVbnZfOWJLM1hZVUVTbE0xamlOX2RaXzU5LWFvdDJxMTdMcVprMERlWEhMV1FSX2FPdGtscTNBMVZmZ2gzcmpfZWdWcFFjRWV2Wnl1REdRVWdDcU5zd0Q5Q0VDcGp3WTRHSjExSzZOekxyaUMxaHJkNmhlVWh5NTBzQ2gybTdCVEhpUEF6RV84NW02TjBFejhiQkFBVjVvYVdnbGVTcG5reHlfbUVybVB5aGxwNFI5WHc?oc=5", "source_name": "Stocktwits", "published_at": "2025-09-22T17:19:49+00:00", "published_display": "22 Sep 2025 17:19", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Actuate Therapeutics Reports Positive Progress on Elraglusib as Backbone Therapy for Pancreatic Cancer Amid Ongoing Clinical Trials and Financing Milestone", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwJBVV95cUxOSU45c1F6Rmw5LWlqeUZyMUYyTnpYT1N0NjJjUkFiTElkRjFscThBeHg2bk1TNmowNTZLNk9tTXFoTVhURzl3NWVZeUgtb1ZjelZrbXFMQnY2OVE1U3JvQTNzekxhLXpuVmd5TVJhdXdFUER3UktSb21kWTgxQ0VneWlrZm1xQjZ0elZUNEY3ZXhyQnZlY0FNeGhEeUJTdDMwVlRpOU1WR3BjcTFEZDNJcVRUNlo4VEdkZmZ6Z3F1dEMtMGVmY2NOVjYwVXdCdEtGbTh0TEdoYkRIOWg5X0pCdXZ5Y0JjalM2Z3ZDYlZCUDF6TFF5QXlhR2xvMkNrVHZ0T0V4eUsweklJYWhsWkdJSnJiMnhqdkk?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-09-22T07:00:00+00:00", "published_display": "22 Sep 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Richtech Robotics Stock Sees Retail Chatter Double In A Day: Analyst Says Company's Longer-Term Visibility Is Improving", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNVXNwWjlGVm90VXg3MVJYZkNwZnRKNzVDRmVwdFVhbFdvTlBBNmJsTTdIYmZQOUZnc3hZcDNCRkYtSG5FTlAxdFhTQ19FYks5R3hVbFRTNzdtOEo3SXdkWXVfdnZtLWtkZnJpazduWG53MnJlVHVpcjh1RVljcFZHb01iUnRxRUIzMzJqT0g4bU40VnlQNlBmMjlGY283MGFEd1BuRDZyb3QzUEdLQzhfYWFzLUlqX3NheHR0Yw?oc=5", "source_name": "Stocktwits", "published_at": "2025-09-22T07:00:00+00:00", "published_display": "22 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 95, "total_relevant": 67, "sentiment_summary": {"positive": 23, "negative": 10, "neutral": 34, "score": 53, "total": 67, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 21.2, "count": 36}, {"event": "earnings", "label": "Earnings", "weight": 10.39, "count": 20}, {"event": "analyst", "label": "Analyst action", "weight": 3.3, "count": 6}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 23, "negative_events": 10}, "market_context": {"has_market_context": true, "latest_close": 1.44, "latest_week": "2026-07-17", "one_week_move": 19.0, "four_week_move": -30.4, "twelve_week_move": -51.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.191411, "market_dynamics_buy_signal": false, "relative_strength": -74.371011, "fair_value_gap": -77.8, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 38.6892, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+19.0% over one week, -30.4% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 9}, {"label": "TradingView", "count": 6}, {"label": "Quiver Quantitative", "count": 5}, {"label": "www.marketscreener.com", "count": 4}, {"label": "TradingKey", "count": 4}, {"label": "GlobeNewswire", "count": 4}, {"label": "Stocktwits", "count": 3}, {"label": "Stock Titan", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 60}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 36}, {"label": "Earnings", "count": 20}, {"label": "Analyst action", "count": 6}, {"label": "Regulatory and legal", "count": 2}, {"label": "Macro sensitivity", "count": 1}, {"label": "Balance sheet", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "60", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "5", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+19.0% over one week, -30.4% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Johnson & Johnson stock trades steadily as diversified healthcare earnings and pipeline support long"}], "updated_at": "2026-07-18T17:27:13.967529+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}